Past and future of an IMI-PharmaTrain (IMI-PhT)-initiated multinational pharmaceutical medicine course at the Semmelweis University in Hungary

• Published in: Frontiers in pharmacology Vol. 15; p. 1394987
• Main Authors: Kerpel-Fronius, S, Gottwald, M, Arányi, P, Renczes, G, Görbe, A, Papp, R, Ferdinandy, P
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 30.04.2024
• Subjects: Cooperative European Medicines Development Course; Innovative Medicines Initiative; medicines development course; pharmaceutical medicine; Pharmacology; PharmaTrain; university education; pharmaceutical medicine; Central and Eastern Europe; Innovative Medicines Initiative; university education; Cooperative European Medicines Development Course; medicines development course; PharmaTrain
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2024.1394987

The pharmaceutical medicine course at the Semmelweis University of Budapest, Hungary, was initiated as part of the Innovative Medicines Initiative (IMI is the main program, IMI-PharmaTrain is one of the IMI projects) Pharmaceutical Medicine Training Programs (16 IMI Call 2008/1/16). The aim was to extend training in the development of pharmaceutical medicine to those EU member states where no such education was present. The final program envisaged the development of a cooperative education supported by universities located in Central and Eastern Europe. It was considered to be the economically and scientifically most viable approach to combine the expertise from these countries to form a united teaching staff and provide education jointly for young professionals of the region. Semmelweis University was selected to manage this coordinated program. In this report, we describe the organization and functioning of this international university-based pharmaceutical medicine education project called the Cooperative European Medicines Development Course (CEMDC) and evaluate its successes and shortcomings. During the pandemic, the educational course was interrupted. The follow-on program is reorganized as a postgraduate MSc course named "Semmelweis Pharma MBA" and will be started in 2025. It will continue the established PharmaTrain educational tradition. However, it will deal in more detail with the transition from basic pharmacological to industrial research, as well as biopharmaceutical formulation and manufacturing and marketing aspects of medicines development.